Arca Biopharma Stock Performance

ABIO
 Stock
  

USD 2.07  0.06  2.82%   

The firm shows a Beta (market volatility) of 0.2084, which signifies not very significant fluctuations relative to the market. Let's try to break down what Arca Biopharma's beta means in this case. As returns on the market increase, Arca Biopharma returns are expected to increase less than the market. However, during the bear market, the loss on holding Arca Biopharma will be expected to be smaller as well. Even though it is essential to pay attention to Arca Biopharma historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy in foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Arca Biopharma exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Arca Biopharma has an expected return of -0.26%. Please be advised to confirm Arca Biopharma value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall to decide if Arca Biopharma performance from the past will be repeated at some point in the near future.
  
Arca Biopharma Performance
0 of 100
Over the last 90 days Arca Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in October 2022. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more

Arca Biopharma Price Channel

Quick Ratio18.04
Fifty Two Week Low1.7100
Fifty Two Week High3.0000

Arca Biopharma Relative Risk vs. Return Landscape

If you would invest  246.00  in Arca Biopharma on June 28, 2022 and sell it today you would lose (39.00)  from holding Arca Biopharma or give up 15.85% of portfolio value over 90 days. Arca Biopharma is currently does not generate positive expected returns and assumes 1.6888% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Arca Biopharma, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Arca Biopharma is expected to under-perform the market. In addition to that, the company is 1.53 times more volatile than its market benchmark. It trades about -0.15 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.07 per unit of volatility.

Arca Biopharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Arca Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arca Biopharma, and traders can use it to determine the average amount a Arca Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1537

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsABIO
Estimated Market Risk
 1.69
  actual daily
 
 14 %
of total potential
 
1414
Expected Return
 -0.26
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.15
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Arca Biopharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arca Biopharma by adding it to a well-diversified portfolio.

About Arca Biopharma Performance

To evaluate Arca Biopharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Arca Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Arca Biopharma Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Arca Biopharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Arca Biopharma's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Things to note about Arca Biopharma

Checking the ongoing alerts about Arca Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arca Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Arca Biopharma Alerts

Equity Alerts and Improvement Suggestions

Arca Biopharma generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (18.49 M) with profit before overhead, payroll, taxes, and interest of 28.37 M.
Arca Biopharma currently holds about 49.06 M in cash with (17.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.etfstrategy.com: BlackRock launches neuroscience-focused healthcare ETF ETF Strategy - ETF Strategy
Please continue to Trending Equities. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.